SNGX (Soligenix Inc.) stock: $0.37, $8.1M market cap, $9.8M cash, -$1.7M EV, $13.0M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Pipeline assets
HyBryte
Phase 3 · Terminated Modality: photodynamic therapy (topical synthetic hypericin + visible light)
Aliases SGX301, synthetic hypericin sodium
Partnerships FDA Orphan Products Development grant-funded investigator-initiated study wound down Jun 2026 with the program.
Indications- Cutaneous T-cell lymphoma (CTCL) (Stage not disclosed)
Status note Photodynamic therapy for CTCL evaluated in the Phase 3 FLASH2 study. The DMC's Apr 2026 interim efficacy analysis recommended halting for futility; the Board terminated the HyBryte development program in Jun 2026 and is winding down the trial.
SGX302
Phase 2 · Active Modality: topical synthetic hypericin
Aliases synthetic hypericin
Status note Synthetic hypericin for psoriasis; company plans to conduct a Phase 2a clinical trial following positive proof-of-concept in a small Phase 1/2 pilot study in mild-to-moderate psoriasis patients.
SGX945 (dusquetide)
Phase 2 · Active Modality: first-in-class Innate Defense Regulator
Target innate immune system
Indications- Aphthous ulcers in Behçet's Disease (Phase 2)
Status note Dusquetide for aphthous ulcers in Behçet's Disease; company plans to conduct a Phase 2 clinical trial following prior studies validating biologic activity.
SGX942 (dusquetide)
Phase 3 · Active Modality: first-in-class Innate Defense Regulator
Target innate immune system
Partnerships Company seeking partner(s) to continue development.
Indications- Oral mucositis in head and neck cancer (Phase 3)
Status note Dusquetide for oral mucositis in head and neck cancer. Following UK MHRA feedback that a second Phase 3 trial would be required to support marketing authorization, the company plans to design a second study and identify partner(s) to continue the program.
Public Health Solutions vaccine programs
Stage not disclosed · Active Modality: vaccine (ThermoVax heat-stabilized)
Partnerships Supported by government grant/contract funding from NIAID, BARDA and the Defense Threat Reduction Agency.
Indications- Ricin toxin exposure (vaccine) (Stage not disclosed)
- Filoviruses (Marburg, Ebola) (vaccines) (Stage not disclosed)
Status note Public Health Solutions segment includes RiVax (ricin toxin vaccine candidate) and filovirus vaccine programs (Marburg, Ebola) using the proprietary ThermoVax heat stabilization platform. Clinical phases not disclosed in the excerpts.
Per-asset detail extracted from the 10-Q filed 2026-08-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.